433 related articles for article (PubMed ID: 27993818)
21. The RNA-binding protein SRSF1 is a key cell cycle regulator via stabilizing NEAT1 in glioma.
Zhou X; Li X; Yu L; Wang R; Hua D; Shi C; Sun C; Luo W; Rao C; Jiang Z; Wang Q; Yu S
Int J Biochem Cell Biol; 2019 Aug; 113():75-86. PubMed ID: 31200124
[TBL] [Abstract][Full Text] [Related]
22. Long noncoding RNA DGCR5 involves in tumorigenesis of esophageal squamous cell carcinoma via SRSF1-mediated alternative splicing of Mcl-1.
Duan Y; Jia Y; Wang J; Liu T; Cheng Z; Sang M; Lv W; Qin J; Liu L
Cell Death Dis; 2021 Jun; 12(6):587. PubMed ID: 34099633
[TBL] [Abstract][Full Text] [Related]
23. The long non-coding RNA MALAT1 promotes the migration and invasion of hepatocellular carcinoma by sponging miR-204 and releasing SIRT1.
Hou Z; Xu X; Zhou L; Fu X; Tao S; Zhou J; Tan D; Liu S
Tumour Biol; 2017 Jul; 39(7):1010428317718135. PubMed ID: 28720061
[TBL] [Abstract][Full Text] [Related]
24. miR-124-3p availability is antagonized by LncRNA-MALAT1 for Slug-induced tumor metastasis in hepatocellular carcinoma.
Cui RJ; Fan JL; Lin YC; Pan YJ; Liu C; Wan JH; Wang W; Jiang ZY; Zheng XL; Tang JB; Yu XG
Cancer Med; 2019 Oct; 8(14):6358-6369. PubMed ID: 31466138
[TBL] [Abstract][Full Text] [Related]
25. LINC00152 promotes proliferation in hepatocellular carcinoma by targeting EpCAM via the mTOR signaling pathway.
Ji J; Tang J; Deng L; Xie Y; Jiang R; Li G; Sun B
Oncotarget; 2015 Dec; 6(40):42813-24. PubMed ID: 26540343
[TBL] [Abstract][Full Text] [Related]
26. SRSF2 Regulates Alternative Splicing to Drive Hepatocellular Carcinoma Development.
Luo C; Cheng Y; Liu Y; Chen L; Liu L; Wei N; Xie Z; Wu W; Feng Y
Cancer Res; 2017 Mar; 77(5):1168-1178. PubMed ID: 28082404
[TBL] [Abstract][Full Text] [Related]
27. mTOR regulates aerobic glycolysis through NEAT1 and nuclear paraspeckle-mediated mechanism in hepatocellular carcinoma.
Zhang H; Su X; Burley SK; Zheng XFS
Theranostics; 2022; 12(7):3518-3533. PubMed ID: 35547764
[No Abstract] [Full Text] [Related]
28. Long Noncoding RNA MALAT1 Contributes to Sorafenib Resistance by Targeting miR-140-5p/Aurora-A Signaling in Hepatocellular Carcinoma.
Fan L; Huang X; Chen J; Zhang K; Gu YH; Sun J; Cui SY
Mol Cancer Ther; 2020 May; 19(5):1197-1209. PubMed ID: 32220970
[TBL] [Abstract][Full Text] [Related]
29. Long Non-Coding RNA MALAT1 Regulates ZEB1 Expression by Sponging miR-143-3p and Promotes Hepatocellular Carcinoma Progression.
Chen L; Yao H; Wang K; Liu X
J Cell Biochem; 2017 Dec; 118(12):4836-4843. PubMed ID: 28543721
[TBL] [Abstract][Full Text] [Related]
30. The long non-coding RNA PFI protects against pulmonary fibrosis by interacting with splicing regulator SRSF1.
Sun J; Jin T; Su W; Guo Y; Niu Z; Guo J; Li L; Wang J; Ma L; Yu T; Li X; Zhou Y; Shan H; Liang H
Cell Death Differ; 2021 Oct; 28(10):2916-2930. PubMed ID: 33981019
[TBL] [Abstract][Full Text] [Related]
31. An Integrated Transcriptomics and Proteomics Analysis Implicates lncRNA MALAT1 in the Regulation of Lipid Metabolism.
Wang H; Zhang Y; Guan X; Li X; Zhao Z; Gao Y; Zhang X; Chen R
Mol Cell Proteomics; 2021; 20():100141. PubMed ID: 34478876
[TBL] [Abstract][Full Text] [Related]
32. LncRNA DCST1-AS1 accelerates the proliferation, metastasis and autophagy of hepatocellular carcinoma cell by AKT/mTOR signaling pathways.
Li J; Zhai DS; Huang Q; Chen HL; Zhang Z; Tan QF
Eur Rev Med Pharmacol Sci; 2019 Jul; 23(14):6091-6104. PubMed ID: 31364110
[TBL] [Abstract][Full Text] [Related]
33. LncRNA MALAT1 promotes migration and invasion of non-small-cell lung cancer by targeting miR-206 and activating Akt/mTOR signaling.
Tang Y; Xiao G; Chen Y; Deng Y
Anticancer Drugs; 2018 Sep; 29(8):725-735. PubMed ID: 29916897
[TBL] [Abstract][Full Text] [Related]
34. LNCAROD enhances hepatocellular carcinoma malignancy by activating glycolysis through induction of pyruvate kinase isoform PKM2.
Jia G; Wang Y; Lin C; Lai S; Dai H; Wang Z; Dai L; Su H; Song Y; Zhang N; Feng Y; Tang B
J Exp Clin Cancer Res; 2021 Sep; 40(1):299. PubMed ID: 34551796
[TBL] [Abstract][Full Text] [Related]
35. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation.
Lai MC; Yang Z; Zhou L; Zhu QQ; Xie HY; Zhang F; Wu LM; Chen LM; Zheng SS
Med Oncol; 2012 Sep; 29(3):1810-6. PubMed ID: 21678027
[TBL] [Abstract][Full Text] [Related]
36. Absence of Malat1 does not prevent DEN-induced hepatocarcinoma in mice.
Miard S; Girard MJ; Joubert P; Carter S; Gonzales A; Guo H; Morpurgo B; Boivin L; Golovko A; Picard F
Oncol Rep; 2017 Apr; 37(4):2153-2160. PubMed ID: 28260109
[TBL] [Abstract][Full Text] [Related]
37. Emerging functions of SRSF1, splicing factor and oncoprotein, in RNA metabolism and cancer.
Das S; Krainer AR
Mol Cancer Res; 2014 Sep; 12(9):1195-204. PubMed ID: 24807918
[TBL] [Abstract][Full Text] [Related]
38. Long noncoding RNA EPB41L4A-AS2 inhibits hepatocellular carcinoma development by sponging miR-301a-5p and targeting FOXL1.
Wang YG; Wang T; Shi M; Zhai B
J Exp Clin Cancer Res; 2019 Apr; 38(1):153. PubMed ID: 30971290
[TBL] [Abstract][Full Text] [Related]
39. CCL21 Induces mTOR-dependent MALAT1 Expression, Leading to Cell Migration in Cutaneous T-Cell Lymphoma.
Hong CH; Lin SH; Lee CH
In Vivo; 2019; 33(3):793-800. PubMed ID: 31028199
[TBL] [Abstract][Full Text] [Related]
40. Oncogenic long noncoding RNA MALAT1 and HCV-related hepatocellular carcinoma.
Toraih EA; Ellawindy A; Fala SY; Al Ageeli E; Gouda NS; Fawzy MS; Hosny S
Biomed Pharmacother; 2018 Jun; 102():653-669. PubMed ID: 29604585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
